Sunday 18 October 2026
Export VANI’s income statement to Excel — free account
Vivani Medical, Inc.
VANI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.7% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.12
0.03
−2.61%
Follow VANI
Vivani Medical, Inc. (VANI) P/E ratio
Vivani Medical, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2019 | 0.0× | — |
| Sep 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| Mar 2019 | 0.0× | — |
| 16 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COYA Coya Therapeutics, Inc. compare | n/m |
| VANI Vivani Medical, Inc. | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| INO Inovio Pharmaceuticals, Inc. compare | n/m |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)